---
layout: default
title: Polatuzumab Vedotin
parent: 僅模型預測 (L5)
nav_order: 283
evidence_level: L5
indication_count: 1
---

# Polatuzumab Vedotin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Polatuzumab Vedotin: From B-cell Lymphoma to HER2 Positive Breast Carcinoma

## One-Sentence Summary

Polatuzumab vedotin is an antibody-drug conjugate (ADC) targeting CD79b, currently approved for B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL). TxGNN predicts a possible link to **HER2 positive breast carcinoma**, but this prediction is currently supported by **no clinical trials and no published literature** — it rests solely on a model score (**Evidence Level L5**).

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies (per drug mechanism description; not present as structured data) |
| Predicted New Indication | HER2 positive breast carcinoma |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L5 |
| Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Polatuzumab vedotin is an antibody-drug conjugate that selectively delivers the cytotoxin MMAE (monomethyl auristatin E) to B cells expressing CD79b, a component of the B-cell receptor complex. It is currently approved for DLBCL and other B-cell malignancies. The evidence pack's structured `original_moa` field is marked as a data gap, but this mechanism can be inferred from the model's rationale text.

HER2 positive breast carcinoma and DLBCL belong to entirely different tumor biology categories — the former is an epithelial tumor driven by HER2 overexpression, while the latter is a hematologic malignancy of B-cell origin. CD79b is not a marker expressed on HER2 positive breast cancer cells, so there is no shared drug target between the original and predicted indications.

Given this, the current prediction should be treated as a statistical association produced by the TxGNN graph model rather than a mechanistically grounded hypothesis. Without any supporting mechanistic, clinical, or literature evidence, this candidate is best classified as a likely false positive at this stage.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Market Information

No marketing authorizations are currently on record for this drug (0 licenses, market status: not marketed).

---

## Cytotoxicity

Polatuzumab vedotin is an antibody-drug conjugate that delivers a cytotoxic payload (MMAE) and is classified as an antineoplastic agent.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy — antibody-drug conjugate (ADC) delivering cytotoxic payload (MMAE) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Must follow cytotoxic drug handling regulations, consistent with ADC/cytotoxic payload agents |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate has Evidence Level L5 — no clinical trials, no literature, and no plausible mechanistic link between the CD79b target and HER2 positive breast carcinoma biology. The prediction currently reflects a model-level statistical association only and does not meet the threshold to advance.

**To proceed, the following is needed:**
- Confirmed mechanism of action (MOA) data from DrugBank (currently a data gap, DG002)
- TFDA package insert warnings, contraindications, and drug interaction data (currently a blocking data gap, DG001)
- Any preclinical or mechanistic evidence connecting CD79b/MMAE pathway activity to HER2 positive breast cancer biology, before further evaluation is warranted
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

